Grifols, S.A (0RDU) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Grifols, S.A €5.88, price €9.55, upside -38.5%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €6.76 – €21.90 · fair‑value band €5.17 – €10.83 · the €9.55 price screens above the €5.88 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Show more
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Stock analysis
Grifols, S.A (0RDU) currently trades at €9.55, while our model-based Fair Value estimate is €5.88, 38.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €12.91 per share, and 7 of the 16 models we run sit above the €9.55 price.
Bear case: the Economic Profit group reads lowest at €3.64, and 9 of the 16 models stay below the price. Evidence for this calculation is medium.
Scenario range: €5.17 (bear) to €10.83 (bull), the price of €9.55 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Grifols, S.A reported revenue of €5.3B in FY2020 versus €4.0B in FY2016, a compound +7.2%/yr. Reported net income was €619M in FY2020, compounding +3.2%/yr from FY2016.
Key figures
Market cap €8.9B · P/S ratio 1.19 · Net margin 11.6% · Return on equity 6.9% · Return on assets (EBIT) 8.0% · Operating margin 15.9% · Revenue (TTM) €7.4B · Revenue growth (YoY) −0.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −38%, 0RDU screens richer than that median.
Fair Value models
Bear €5.17Fair Value €5.88Bull €10.83
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
23.2% (2016) → 18.7% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Grifols, S.A Fair Value". https://www.fairvalue-calculator.com/stock/0RDU
Frequently asked questions
Is Grifols, S.A (0RDU) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €5.88 versus a price of €9.55, about −38% upside (overvalued).
What is the fair value of 0RDU?
Our model-based fair value for Grifols, S.A is €5.88 (as of Sep 23, 2026), built from audited fundamentals. The current price: €9.55.
What is the quality score of 0RDU?
Grifols, S.A has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Grifols, S.A (0RDU)?
Our model-based price target is the fair value of €5.88 (as of Sep 23, 2026) from 16 valuation models. Cautious scenario €5.17, optimistic scenario €10.83. It is a calculation from audited fundamentals, not an analyst target.
What is the Grifols, S.A stock forecast for 2026?
Our models put fair value at €5.88, about −38% upside versus a price of €9.55 (overvalued). Cautious scenario €5.17, optimistic scenario €10.83. The calculation is refreshed regularly with new filings.
What is the revenue of Grifols, S.A (0RDU)?
Grifols, S.A reported trailing-twelve-month revenue of about €7.4B (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Grifols, S.A (0RDU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Grifols, S.A it is €5.88 per share (as of Sep 23, 2026), against a price of €9.55. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Grifols, S.A stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 0RDU trades above its calculated fair value: price €9.55, fair value €5.88, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RDU?
No. The price is what the market pays today (€9.55); the fair value is what the company's own numbers justify (€5.88). For Grifols, S.A the two are €3.67 per share apart. That gap is exactly why we show both numbers side by side.
How much is Grifols, S.A worth?
The market values Grifols, S.A at about €8.9B (market capitalisation, as of Sep 23, 2026). Per share that is €9.55; our models calculate a fair value of €5.88 per share.
What do the bullish and bearish scenarios say about 0RDU?
Our models span a range for Grifols, S.A: cautious scenario €5.17, base €5.88, optimistic €10.83 per share (as of Sep 23, 2026, price €9.55). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0RDU from its 52-week high?
Grifols, S.A trades at €9.55, about 24% below its 52-week high of €12.50 and 11% above the low of €8.59 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €5.88 is for.
Which stocks are comparable to Grifols, S.A?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Grifols, S.A stock attractive at the current price?
The data as of Sep 23, 2026: price €9.55, calculated fair value €5.88 (−38%), Quality Score 41/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RDU calculated?
We run Grifols, S.A through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €5.88, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Grifols, S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Grifols, S.A (0RDU)?
The closing price on Oct 2, 2026 was €9.55. Our model-based fair value is €5.88, about −38% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Grifols, S.A right now?
Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (€5.17 to €10.83) leaves room in how you read the outcome.
Key figures of Grifols, S.A
How large is the market capitalisation of Grifols, S.A (0RDU)?
The market capitalisation of Grifols, S.A is €8.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Grifols, S.A (0RDU)?
The price-to-sales ratio of Grifols, S.A is 1.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Grifols, S.A (0RDU)?
The net margin of Grifols, S.A is 11.6% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Grifols, S.A (0RDU)?
The return on equity (ROE) of Grifols, S.A is 6.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Grifols, S.A (0RDU)?
On an EBIT basis the return on assets of Grifols, S.A is 8.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Grifols, S.A (0RDU)?
The operating margin of Grifols, S.A is 15.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Grifols, S.A (0RDU)?
Revenue at Grifols, S.A is growing −0.9% versus a year earlier (3y avg +7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Grifols, S.A (0RDU)?
Earnings per share at Grifols, S.A are growing +32.9% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
